# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $34 price target.
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.57) ...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomize...
Anaptys to receive $50 million upfront cash payment from Sagard Healthcare Prior agreement amended to now expire once Sagard re...
Leerink Partners analyst David Risinger initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Outperform rating and announce...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...
Wells Fargo analyst Derek Archila initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Pric...